Medical physics

NorthShore Neurosurgeon First in Illinois to Offer New Targeted Therapy for Brain Tumors

Wednesday, June 3, 2020 - 4:37pm

EVANSTON, Ill., June 3, 2020 /PRNewswire/ -- NorthShore University HealthSystem (NorthShore) neurosurgeon, Julian Bailes, MD , is the first in Illinois to begin offering GammaTile Therapy, a new approach to treating malignant brain tumors.

Key Points: 
  • EVANSTON, Ill., June 3, 2020 /PRNewswire/ -- NorthShore University HealthSystem (NorthShore) neurosurgeon, Julian Bailes, MD , is the first in Illinois to begin offering GammaTile Therapy, a new approach to treating malignant brain tumors.
  • TheFDA-cleared, Surgically Targeted Radiation Therapy (STaRT) is designed to delay tumor regrowth for patients with high grade gliomas, meningiomas and brain metastases.
  • Aggressive brain tumors tend to be resistant to current treatments and have a high likelihood of recurrence.
  • GammaTile Therapy is a radiation therapy specifically designed for implantation in the brain and offers advantages for patients undergoing surgery for brain tumors.

TAE Life Sciences Secures $30M in Initial B Round Phase to Accelerate Development of Unique Boron Delivery Drugs for Novel Cancer Treatment

Tuesday, June 2, 2020 - 3:05pm

The initial phase of the B-round funds comes from a consortium of investors including ARTIS Ventures, who led the company's initial funding in 2018.

Key Points: 
  • The initial phase of the B-round funds comes from a consortium of investors including ARTIS Ventures, who led the company's initial funding in 2018.
  • BNCT is a particle therapy designed to selectively destroy cancer cells without damaging neighboring healthy cells.
  • The TLS diversified drug program objectives include improved targeting of cancer cells, increased boron accumulation in target cells, longer boron retention time, and more boron homogeneity.
  • The drugs and machine being developed by TAE Life Sciences is currently for investigational use only and has not been approved for sale or commercial use.

New Medical Facilities Opening in Richmond Aim to Deliver High Quality Radiology at Lower Cost

Tuesday, June 2, 2020 - 1:55pm

RICHMOND, Va., June 2, 2020 /PRNewswire/ -- Lower-cost, high-quality radiology services are coming to Richmond with the opening of two new medical facilities.

Key Points: 
  • RICHMOND, Va., June 2, 2020 /PRNewswire/ -- Lower-cost, high-quality radiology services are coming to Richmond with the opening of two new medical facilities.
  • The new offices are near the I-64/West Broad/Glenside Drive interchange in a building that is home to other medical specialists.
  • Dominion Imaging ( dominionimaging.com ) provides diagnostic radiology services including X-ray and ultrasound.
  • The facilities planned to open earlier this spring but decided to delay appointments due to the pandemic.

Second Ten Year Data Report Demonstrates Efficacy of Isoray’s Cesium-131 Internal Radiation Therapy in the Treatment of Prostate Cancer

Tuesday, June 2, 2020 - 1:13pm

The authors concluded that the study demonstrates that, Prostate brachytherapy treated with Cesium-131 achieves excellent long-term biochemical control.

Key Points: 
  • The authors concluded that the study demonstrates that, Prostate brachytherapy treated with Cesium-131 achieves excellent long-term biochemical control.
  • Woods noted that emerging treatment strategies for localized prostate cancer require years of follow-up, given the long natural history of this cancer.
  • Cesium-131 has the shortest half-life and highest energy of brachytherapy seeds commonly used in the treatment of prostate cancer.
  • Unlike external beam radiation, Cesium-131 internal radiation therapy is able to deliver a precise dosage and placement of Cesium-131 seeds, leaving healthy tissues and organs undamaged.

Salvage focal ablative therapy for radio-recurrent prostate cancer is safe and provides good short to medium-term oncological control

Tuesday, June 2, 2020 - 12:00pm

An alternative is radical salvage surgery (called salvage prostatectomy) which removes what is left of the prostate after radiation.

Key Points: 
  • An alternative is radical salvage surgery (called salvage prostatectomy) which removes what is left of the prostate after radiation.
  • Focal therapy uses different forms of energy, noninvasively or minimally invasively, to target and treat selectively only those regions of the prostate where cancer has recurred.
  • Prost8 UK charity: 1182590 is a UK charity concentrating on the major advances in minimally invasive prostate cancer treatment enabled through focal therapy.
  • Men who are concerned about prostate cancer should in the first instance discuss this with their family doctor (GP).

Ezra Raises $18M Series A Led By FirstMark Capital

Monday, June 1, 2020 - 3:00pm

Ezra will use the new funding to expand its medical imaging AIs to make MRI-based cancer screening more accessible.

Key Points: 
  • Ezra will use the new funding to expand its medical imaging AIs to make MRI-based cancer screening more accessible.
  • Ezra will offer 50 free plans to medical providers and first responders who have been on the frontlines of COVID-19.
  • Ezra partners with existing outpatient imaging facilities, and all Ezra scans are analyzed by board-certified radiologists.
  • FirstMark Capital is an early-stage venture capital firm based in New York City.

RadNet, Inc. to Present at the Jefferies 2020 Virtual Healthcare Conference on June 2, 2020

Monday, June 1, 2020 - 11:00am

RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue.

Key Points: 
  • RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue.
  • RadNet has a network of 335 owned and/or operated outpatient imaging centers.
  • In addition, RadNet provides radiology information technology solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry.
  • Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 8,600 employees.

Nanobiotix Announces Positive First Results From Phase I Expansion in Locally Advanced Head and Neck Cancer at ASCO 2020

Friday, May 29, 2020 - 5:02pm

The data were published as part of the virtual scientific program at the 2020 annual meeting of the American Society for Clinical Oncology (ASCO).

Key Points: 
  • The data were published as part of the virtual scientific program at the 2020 annual meeting of the American Society for Clinical Oncology (ASCO).
  • To date, 40 patients have been recruited, 30 of whom are evaluable for efficacy and are included in the data presented at ASCO 2020.
  • Regarding the new, expansion part data, analysis of 40 patients dosed showed that NBTXR3 activated by radiation therapy remains safe and well tolerated.
  • In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers.

Vivos Inc Resumes IsoPet Animal Cancer Therapy

Friday, May 29, 2020 - 12:00pm

Richland WA, May 29, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc Resumes IsoPet Animal Cancer Therapy

Key Points: 
  • Richland WA, May 29, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc Resumes IsoPet Animal Cancer Therapy
    After several months of virus-related stand-down IsoPet therapy has been scheduled for the week of June 20.
  • Vivos Inc. has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (Isopet) and in humans (Radiogel).
  • The Isopet Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers.
  • Following this demonstration phase, Vivos can generate revenues through the sale of Isopet to University animal hospitals and private veterinary clinics.

RefleXion Announces Clinical Collaboration to Evaluate Biology-guided Radiotherapy With Merck’s KEYTRUDA® for Certain Late-Stage Cancers

Thursday, May 28, 2020 - 2:00pm

This image depicts two 90-degree PET arcs that sense tumor emissions to guide radiotherapy delivery.

Key Points: 
  • This image depicts two 90-degree PET arcs that sense tumor emissions to guide radiotherapy delivery.
  • Worldwide, over 1,000 clinical trials registered with the National Institutes of Health seek to determine the effect of combining immunotherapy and radiotherapy.
  • Currently, the RefleXion machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT), all different techniques of EBRT.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA